Coronavirus disease (COVID-19) still represents a major global health threat as the majority of the world's population remains susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) \[[@r1]-[@r3]\]. The proportion of infections resulting in a fatal outcome, known as infection fatality ratio (IFR), and the associated risk factors are still poorly quantified for SARS-CoV-2 \[[@r1],[@r4]\].

The aim of this study was to provide estimates of SARS-CoV-2 IFR stratified by age, sex and comorbidities and to investigate the risk factors for fatal outcome in SARS-CoV-2-infected people.

Study population and sample description
=======================================

The study population comprised contacts of COVID-19 cases identified through contact tracing conducted in Lombardy, Italy between February and April 2020. For these subjects, we analysed reverse-transcription PCR (RT-PCR) results from nasopharyngeal swabs administered during the contact tracing activity. These data were complemented with the results of an ongoing serological survey on the same group of individuals that started on 16 April 2020. Finally, we also collected information on comorbidities (respiratory, cardiovascular, metabolic and oncological) and clinical outcomes of each case reported in the Lombardy linelist of COVID-19 patients (last update: 8 June 2020).

The data analysed here represent a selection from a database of 62,881 contacts of COVID-19 cases. We selected only contacts belonging to clusters (i.e. groups of contacts identified by one positive index case) where all individuals were tested against SARS-CoV-2 infection either through nasal swabs during the contact tracing operations or through retrospective IgG serological testing. To avoid possible biases, we excluded the index cases as they were often identified because of their symptoms and may therefore have been at higher risk of severe disease. The accuracy of IgG testing and RT-PCR used in our sample was assessed in \[[@r5],[@r6]\]. The IFR was computed as the proportion of deaths that occurred among all SARS-CoV-2-positive contacts identified in the considered sample, here defined as subjects with at least one laboratory confirmation of their infection.

Overall, we analysed 5,484 contacts (median age: 50 years; IQR: 30--61; 43.7% male). Of those, 1,364 (25%) were tested only by an RT-PCR assay targeting different SARS-CoV-2 genes during the contact tracing activities \[[@r5]\], 3,493 (64%) were tested only by a serological assay for IgG neutralising antibodies against S1/S2 antigens \[[@r6]\] at least a month after the reporting date of their index case and 627 (11%) were tested both by RT-PCR and serology. Among the 5,484 analysed individuals, 2,824 resulted positive to SARS-CoV-2 (median age: 53 years; IQR: 34--64; 43.2% male) and 62 of the positive individuals died with a COVID-19 diagnosis (median age: 79 years; IQR: 74--83; 53.2% male).

Estimates of the infection fatality ratio stratified by age, sex, and comorbidities
===================================================================================

We performed a univariate analysis and estimated the mean IFR at 10.5% (95% confidence interval (CI): 8.0--13.6) for individuals 70 years and older and at 0.43% (95% CI: 0.21--0.79) for those younger than 70 years ([Table 1](#t1){ref-type="table"} and [Figure](#f1){ref-type="fig"}). No deaths were recorded among individuals younger than 50 years. The IFR was higher in men than in women: 14.0% (95% CI:  9.4--19.7) vs 8.3% (95% CI: 5.5--12.1) in subjects 70 years and older and 0.58% (95% CI: 0.21--1.27%) vs 0.31% (95% CI: 0.08--0.78) in younger subjects. The IFR was remarkably lower for patients associated with clusters identified after 16 March 2020 (the median date of confirmation among index cases in the considered clusters), especially among infections in people 80 years and older: 3.70% (95% CI: 0.45--12.8) vs 28.2% (95% CI: 15.0--44.9) in women and 15.6% (95% CI: 5.28--32.8) vs 33.3% (95% CI: 17.3--52.8) in men. In our sample, 51 of 62 deaths occurred in patients affected by cardiovascular diseases (which include hypertension, hypercholesterolemia, myocardiopathy, heart failure, ischemic and valve cardiopathy, arterial and venous vasculopathy). The IFR for subjects with this comorbidity was 22.44% (95% CI: 16.15--29.80) before 16 March 2020 and 9.68% (95% CI: 5.52--15.46) after. The sample size was too small for a useful multivariate analysis.

###### Sample description and infection fatality ratio estimates by sex, age group and comorbidities, close contacts of COVID-19 cases, Lombardy, Italy, February--April 2020 (n = 5,484)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          Any time (n = 5,484)   Before 16 March 2020 (n = 2,696**^a^**)   After 16 March 2020 (n = 2,721**^a^**)                                                                               
  ----------------------- ---------------------- ----------------------------------------- ---------------------------------------- ---------------- ------- ------- ---- ---------------- ------- ------- ---- ---------------
  **Age (years)**                                                                                                                                                                                               

  0--19                   692                    304                                       0                                        0\               273     114     0    0\               413     188     0    0\
                                                                                                                                    (0--1.21)                             (0--3.18)                             (0--1.94)

  20--49                  1,951                  885                                       0                                        0\               951     438     0    0\               973     431     0    0\
                                                                                                                                    (0--0.42)                             (0--0.84)                             (0--0.85)

  50--59                  1,241                  648                                       3                                        0.46\            663     354     2    0.56\            560     283     1    0.35\
                                                                                                                                    (0.1--1.35)                           (0.07--2.03)                          (0.01--1.95)

  60--69                  867                    494                                       7                                        1.42\            448     259     4    1.54\            409     227     2    0.88\
                                                                                                                                    (0.57--2.9)                           (0.42--3.91)                          (0.11--3.15)

  70--79                  485                    335                                       23                                       6.87\            253     189     15   7.94\            229     143     8    5.59\
                                                                                                                                    (4.4--10.12)                          (4.51--12.75)                         (2.45--10.73)

  ≥ 80                    248                    158                                       29                                       18.35\           108     69      21   30.43\           137     86      7    8.14\
                                                                                                                                    (12.65--25.28)                        (19.92--42.69)                        (3.34--16.05)

  **Sex^b^**                                                                                                                                                                                                    

  Male                    2,398                  1,220                                     33                                       2.7\             1,114   587     23   3.92\            1,254   615     9    1.46\
                                                                                                                                    (1.87--3.78)                          (2.5--5.82)                           (0.67--2.76)

  Female                  3,086                  1,604                                     29                                       1.81\            1,582   836     19   2.27\            1467    743     9    1.21\
                                                                                                                                    (1.21--2.59)                          (1.37--3.53)                          (0.56--2.29)

  **Comorbidities^b^**                                                                                                                                                                                          

  None                    122                    113                                       1                                        0.88\            53      49      0    0\               69      64      1    1.56\
                                                                                                                                    (0.02--4.83)                          (0--7.25)                             (0.04--8.4)

  Cardiovascular^c^       350                    316                                       51                                       16.14\           173     156     35   22.44\           172     155     15   9.68\
                                                                                                                                    (12.26--20.67)                        (16.15--29.8)                         (5.52--15.46)

  Respiratory^c^          50                     49                                        8                                        16.33\           23      23      6    26.09\           24      24      2    8.33\
                                                                                                                                    (7.32--29.66)                         (10.23--48.41)                        (1.03--27)

  Oncological^c^          106                    92                                        11                                       11.96\           55      51      6    11.76\           47      38      4    10.53\
                                                                                                                                    (6.12--20.39)                         (4.44--23.87)                         (2.94--24.8)

  Diabetes/metabolic^c^   93                     79                                        13                                       16.46\           43      37      11   29.73\           48      40      2    5\
                                                                                                                                    (9.06--26.49)                         (15.87--46.98)                        (0.61--16.92)

  Unknown                 4,947                  2,335                                     9                                        0.39\            2,437   1,186   6    0.51\            2,452   1,114   2    0.18\
                                                                                                                                    (0.18--0.73)                          (0.19--1.1)                           (0.02--0.65)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI: confidence interval; IFR: infection fatality ratio; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

^a^ Information on the epidemic period was not available for 67 close case contacts, including 43 SARS-CoV-2 infections and two deaths.

^b^ Estimates obtained by aggregating the sample irrespective of age should be cautiously interpreted as the sample may not reflect age-specific SARS-CoV-2 immunity in the population.

^c^ Patients with more than one comorbidity are counted multiple times.

![Age-specific estimates (mean) of infection fatality ratio, SARS-CoV-2-positive contacts, Lombardy, Italy, February--April 2020 (n = 2,824)](2001383-f1){#f1}

Risk factors associated with fatal outcome
==========================================

To identify the risk factors associated with fatal outcome after SARS-CoV-2 infection, we applied a generalised linear model (GLM with logit link) relating the observed outcome (death vs survival) to the sex and the age group (0--59, 60--69, 70--79, ≥ 80 years) of the exposed individuals, to the presence of comorbidities (none, cardiovascular, others), and to the epidemic period of the observed outcomes (before or after 16 March 2020).

We found that individuals younger than 70 years were at a significantly lower risk of death after infection than older patients (Tukey test: p value \< 0.001). The relative risk (RR) of death was 1.81 higher in men than in women (95% CI: 1.03--3.16; Tukey test: p value \< 0.001) and 5.6 times higher for patients affected by cardiovascular comorbidities (95% CI: 1.2--55.3) compared with otherwise healthy individuals, although the latter difference was not statistically significant (Tukey test: p value = 0.29). Finally, the risk of death was 62% lower (95% CI: 31--80%; Tukey test: p value \< 0.001) during the second phase of the epidemic ([Table 2](#t2){ref-type="table"}).

###### Estimated relative risk of death after SARS-CoV-2 infection, Lombardy, Italy, SARS-CoV-2-positive contacts, Lombardy, Italy, February--April 2020 (n = 2,824)

                         SARS-CoV-2-positive   Deaths   RR (95% CI)
  ---------------------- --------------------- -------- --------------------
  **Age (years)**                                       
  ≥ 80                   158                   29       Reference
  0--59                  1,837                 3        0.03 (0.01--0.1)
  60--69                 494                   7        0.14 (0.05--0.32)
  70--79                 335                   23       0.5 (0.27--0.89)
  **Sex**                                               
  Female                 1,604                 29       Reference
  Male                   1,220                 33       1.81 (1.03--3.16)
  **Comorbidity**                                       
  None                   113                   1        Reference
  Cardiovascular         316                   51       5.64 (1.17--55.27)
  Other comorbidity      60                    1        0.93 (0.04--20.55)
  Unknown                2,335                 9        0.36 (0.06--6.42)
  **Epidemic period**                                   
  Before 16 March 2020   1,423                 42       Reference
  After 16 March 2020    1,358                 18       0.38 (0.2--0.69)
  Unknown                43                    2        3.09 (0.43--10.94)

CI: confidence interval; RR: relative risk of death after infection; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

We used a generalised linear model where the fatal outcome is used as the response variable and sex, age group, comorbidities and epidemic period are considered as regressors.

We also performed regression analyses by adding interaction terms to the specifications used in the main analysis. These models were inferior in terms of likelihood ratios ruling out the possible nonlinearities. We also considered a model explicitly accounting for the number of comorbidities but did not observed a statistically significant correlation.

Discussion
==========

Estimates of the IFR are key to evaluating the health impact of epidemics and the effectiveness of control strategies \[[@r2],[@r7]\]. Given the high proportion of asymptomatic and pauci-symptomatic SARS-CoV-2 infections \[[@r8],[@r9]\], it is difficult to estimate the IFR from surveillance data \[[@r1],[@r2],[@r7]\]. In addition, the proportion of ascertained cases over all infections can change dramatically across regions and over time \[[@r2],[@r7]\]. The increasing availability of serological data can assist precise and direct measurements of the IFR. Literature estimates available so far are highly variable (ranging from 0.07% to 1.6%) \[[@r1],[@r2],[@r4],[@r10],[@r11]\], based on small non-random samples \[[@r9]\], data pooled from heterogeneous populations \[[@r1],[@r2],[@r4],[@r10]\] or derived through modelling analyses \[[@r2]\].

Our age-specific estimates of the IFR compare well with results from previous studies in China \[[@r2]\] and Switzerland \[[@r12]\]. More than 80% of the deaths recorded in our sample occurred in patients with cardiovascular diseases, the most common comorbidity among patients hospitalised in the early phase of the Italian epidemic \[[@r3]\]. Owing to the limited sample size we are unable to provide solid estimates of the IFR stratified by both age and comorbidities. However, our results suggest that the higher number of COVID-19 deaths reported in Italy compared with other countries may be due to the high proportion of older individuals in the Lombardy population (28.7% of people older than 60 years vs the European average 25.7%) or to differences in the prevalence of chronic diseases. Our estimates should also be interpreted in light of the specific area and time period considered here, mirroring a health system under severe strain because of the rapid increase in patients requiring intensive care \[[@r3]\]. These conditions combined with the initial scant evidence on appropriate treatments may well have affected the health system's capacity to cope with severe cases. This hypothesis is supported by the remarkable difference in the IFR estimates for clusters identified before and after 16 March.

The age distribution in our sample reflects that of the Lombardy population ([Supplementary Figure S1](/content/10.2807/1560-7917.ES.2020.25.31.2001383#supplementary_data)). However, the data considered in this study represent a sample of individuals who were exposed to COVID-19 cases. Therefore, the reported infection attack rates cannot be considered as representative for the entire region. This also means that estimates of the overall IFR that could be computed by aggregating the entire sample irrespective of age (namely: 2.2%), although compliant with the range of IFR obtained for Spain (between 1% and 2% \[[@r1]\]), should be interpreted with caution. Similar arguments apply for the estimated IFR in men and women when not disaggregated by age.

A limitation of this analysis is that infections were identified in two different periods of time and using different tests (RT-PCR and IgG serological assays). In our sample, all contacts were followed to detect possible symptoms in the time interval form the exposure to the end of the observation period, but while symptomatic individuals were tested by PCR shortly after their index case was identified, IgG serological tests were performed on individuals more than 1 month after their identification as contacts. These features minimise potential biases related to identification of infections and deaths or to seroconversion delays. However, of 327 contacts tested by both RT-PCR and serology, 137 resulted negative in RT-PCR and positive in serology ([Supplementary Table S1](/content/10.2807/1560-7917.ES.2020.25.31.2001383#supplementary_data)). We explored to what extent failures in RT-PCR testing may have affected estimates of the overall IFR, by considering a worst-case scenario where 41.9% (i.e. 137/327) of negative contacts who were tested with RT-PCR only (n = 732) were assumed to be positive. The estimated IFR in this case becomes ca 8% smaller than the one obtained with the baseline analysis (12% and 4% before and after 16 March 2020, respectively; for details see the [Supplement](/content/10.2807/1560-7917.ES.2020.25.31.2001383#supplementary_data)). We explored to what extent false-positive results arising from IgG testing (specificity: 98.3% \[[@r11]\]) may have impacted estimates on the overall IFR, by considering a worst-case scenario where 1.7% of the 1,892 positive contacts who were tested with IgG and were not confirmed by positive RT-PCR results were assumed to be negative. The differences to the baseline estimates were negligible ([Supplement](/content/10.2807/1560-7917.ES.2020.25.31.2001383#supplementary_data)).

Conclusion
==========

The estimates provided here can be considered a robust representation of the IFR during the COVID-19 epidemic in Lombardy, the most affected Italian region \[[@r3],[@r5]\]. These results can be instrumental in evaluating the expected burden of possible future outbreaks. The indication on the key factors that strongly influence the SARS-CoV-2 IFR could be used to inform targeted interventions and possible future COVID-19 vaccination campaigns.
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